1.15Open1.15Pre Close0 Volume30 Open Interest4.00Strike Price0.00Turnover314.08%IV2.18%PremiumDec 20, 2024Expiry Date1.04Intrinsic Value100Multiplier26DDays to Expiry0.11Extrinsic Value100Contract SizeAmericanOptions Type0.7577Delta0.0737Gamma2.46Leverage Ratio-0.0258Theta0.0013Rho1.86Eff Leverage0.0042Vega
Candel Therapeutics Stock Discussion
5.30+
Now Let's Get That 10.+ Back!
Let's Get 5.+
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Candel Therapeutics announced preclinical results for CAN-3110 in melanoma models, showing potential expansion beyond high-grade glioma treatment. CAN-3110, a first-in-class HSV-1 oncolytic viral immunotherapy, demonstrated potent antitumor activity in both in vitro human cel...
No comment yet